Compare ACADIA Pharmaceuticals Inc. (ACAD) vs NetEase Inc (NTES) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs NetEase Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.82 (market cap $4.49B), while NetEase Inc trades at $134.05 (market cap $83.83B). The key difference: NetEase Inc is far larger — about 18.7× ACADIA Pharmaceuticals Inc.'s market cap, and NetEase Inc pays a 2.31% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | NTES | |
|---|---|---|
Market Cap | $4.49B | $83.83B |
Sector | Health | Media |
52-Week High | $28.06 | $159.34 |
52-Week Low | $20.06 | $109.26 |
Enterprise Value | $3.69B | $60.31B |
Dividend Yield | — | 2.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
NetEase (NTES) trades at $130.82, up 2.81% today, with a bullish technical outlook supported by moving averages. The company reported strong Q1 2026 earnings that beat estimates, with revenue growth to $112.63B in 2025 and a net income margin of 29.84%. Recent news highlights international expansion and a $0.72 dividend payment scheduled for June 2026.
The stock presents a compelling value with a P/E of 16.83 and robust profitability metrics. Analyst consensus is strongly bullish with 82% buy ratings and a 34.7% upside potential. Key risks include reliance on the Chinese market and competitive pressures in gaming. Cash flow trends show volatility, but the balance sheet remains strong with $137.58B in cash.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About NetEase Inc
NetEase, which started on an internet portal service in 1997, is a leading online services provider in China. Its key services include online/mobile games, cloud music, media, advertising, email, live streaming, online education, and e-commerce. The company develops and operates some of the China's most popular PC client and mobile games, and it partners with global leading game developers, such as Blizzard Entertainment and Mojang (a Microsoft subsidiary).
Read more on NTES →
